期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 53, 期 17, 页码 6361-6367出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm100487z
关键词
-
资金
- National Cancer Institute, National Institutes of Health [R01CA109025]
- Breast Cancer Research Foundation
- Susan G. Komen Foundation
- University of Michigan Cancer Center [P30CA046592]
A series of compounds were designed and synthesized as antagonists of cIAP-1/2 and XIAP based upon our previously identified lead compound SM-122 (1). The most potent of these (7) binds to XIAP, cIAP-1, and cIAP-2 proteins with K(i) values of 36, <1, and <1.9 nM, respectively. Consistent with its potent binding affinities to IAPs, 7 effectively antagonizes XIAP in a cell-free caspase-9 functional assay, efficiently induces cIAP-1 degradation in cells at concentrations as low as 10 nM, and triggers activation of caspases and PARP cleavage in the MDA-MB-231 breast cancer cell line. Compound 7 potently inhibits cell growth in the MDA-MB-231 cancer cell line with an IC(50) value of 200 nM and is 9 times more potent than compound 1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据